<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Decreases in intrinsic NO cause <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasms</z:e> because of the dysregulation of cGMP formation by NO-mediated pathways </plain></SENT>
<SENT sid="1" pm="."><plain>Because 5-<z:chebi fb="0" ids="30364">cyclopropyl</z:chebi>-2-{1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]<z:chebi fb="0" ids="51642">pyridin-3-yl</z:chebi>}<z:chebi fb="0" ids="38616">pyrimidin-4-ylamine</z:chebi> (BAY 41-2272) is a potent soluble guanylyl cyclase (sGC) stimulator in an NO-independent manner, this study aimed to investigate the mechanisms underlying the relaxant effects of BAY 41-2272 in the rat basilar artery </plain></SENT>
<SENT sid="2" pm="."><plain>BAY 41-2272 (0.0001 to 1 micromol/L) induced relaxations in a concentration-dependent manner, with pEC50 values of 8.13+/-0.03 and 7.63+/-0.05 in intact and denuded rings, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>The sGC inhibitor <z:chebi fb="8" ids="29300">1H-</z:chebi>[1,2,4] oxadiazolo [4,3,-a]quinoxalin-1-one (ODQ) markedly displaced the curve for BAY 41-2272 to the right in intact or denuded rings (&amp;10-fold) </plain></SENT>
<SENT sid="4" pm="."><plain>The NO synthesis inhibitor NG-<z:chebi fb="13" ids="29785">nitro</z:chebi>-<z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi> caused a rightward shift in the curve for BAY 41-2272 (4-fold), whereas the phosphodiesterase type 5 inhibitor sildenafil enhanced BAY 41-2272-induced relaxations (3- to 4-fold) </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:chebi fb="1" ids="29101">Na+</z:chebi>-K+-ATPase inhibitor <z:chebi fb="0" ids="7805">ouabain</z:chebi> caused 3-fold rightward shifts in the curves for BAY 41-2272 </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="29108">Ca2+</z:chebi>-induced contractions in K+ depolarized rings were significantly attenuated by BAY 41-2272 in an ODQ-insensitive manner </plain></SENT>
<SENT sid="7" pm="."><plain>The NO donor <z:chebi fb="2" ids="24364">glyceryl</z:chebi> trinitrate and BAY 41-2272 caused rightward shifts in the contractile responses to <z:chebi fb="19" ids="28790">serotonin</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Their coincubation caused a synergistic inhibition of <z:chebi fb="19" ids="28790">serotonin</z:chebi>-induced contractions </plain></SENT>
<SENT sid="9" pm="."><plain>BAY 41-2272 and <z:chebi fb="2" ids="24364">glyceryl</z:chebi> trinitrate increased cGMP levels (but not cAMP) by 10-fold and 4-fold above baseline, respectively, in an ODQ-sensitive manner </plain></SENT>
<SENT sid="10" pm="."><plain>cGMP levels increased by 50-fold after coincubation </plain></SENT>
<SENT sid="11" pm="."><plain>BAY 41-2272 potently relaxes the rat basilar artery in a synergistic fashion with NO </plain></SENT>
<SENT sid="12" pm="."><plain>Targeting the sGC with selective activators, such as BAY 41-2272, may represent a new therapy to treat cerebrovascular disease </plain></SENT>
</text></document>